Feasibility of 11C-MET PET/MRI Imaging in Pediatric Brain Fossa Tumors (TI-TFCE)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03977896|
Recruitment Status : Not yet recruiting
First Posted : June 6, 2019
Last Update Posted : September 25, 2019
Brain tumors are the most common solid tumors in children and are the second most common cause of cancer-related death among this population. Posterior brain fossa tumors represent about 50% of children brain tumors.
Recently, knowledge in molecular biology has permitted to identify different tumors subgroups of very different prognosis. Today, surgery removal of the tumor is the mandatory. Neuro-oncological treatment differs depending on the histological and molecular subgroup. With classical Magnetic Resonance Imaging (cMRI), distinction between different types of posterior fossa tumors remains difficult.
Positron Emission Tomography combined with MRI (PET/MRI) has proven its benefits for the management of brain tumors. The direct spatiotemporal correlation makes possible the assessment of metabolic, anatomical and functional information. PET/MRI would provide precisions on the pre-therapeutic characterization of tumors, which could permit to modify the patients' care.
L- [methyl-11C] methionine (11C-MET) is currently the gold-standard tracer used in neuro-oncology, but few data exists in children. 11C-MET PET/MRI assessment seems promising, but has not been studied enough. To the best of our knowledge, there is no specific study on primary brain tumors of the posterior fossa in children using 11C-MET PET/MRI.
The primary objectives of this first pilot study is to evaluate the practical feasibility of 11C-MET PET/MRI imaging (machine accessibility and imaging interpretability) before surgery in a population of children older than 5 years old with posterior fossa tumors.
The secondary objectives aim to describe :
- the PET/MRI parameters of the different tumors studied,
- and the patient's participation acceptation.
This feasibility study will allow us to standardize the PET/MRI measurements; this could allow us to discriminate, in a larger study, the different tumor subgroups before surgery.
|Condition or disease||Intervention/treatment||Phase|
|Posterior Brain Fossa Tumors in Children||Procedure: 11C-MET PET/MRI||Not Applicable|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||10 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Pilot Study to Evaluate the Feasibility of Hybrid Brain Imaging 11C-MET PET/MRI of Posterior Brain Fossa Tumors in Children|
|Estimated Study Start Date :||October 2019|
|Estimated Primary Completion Date :||October 2020|
|Estimated Study Completion Date :||October 2020|
|Experimental: 11C-MET PET/MRI||
Procedure: 11C-MET PET/MRI
Except PET/MRI imaging, all the examinations will be done according to the patient's usual care.
PET/MRI imaging will be realized within max 7 days after children enrollment, and the surgery (usual care) will be performed within max 4 days after PET/MRI imaging.
PET/MRI imaging will include the following sequences: T1axial, Diffusion, Magnetic susceptibility post-Gadolinium injection, 3DT1 pre and post-Gadolinium injection, and Arterial Spin Labelling Imaging (ASL).
- number of patients who performed the PET/MRI [ Time Frame: 7 days ]
- number of patients called in for PET/MRI who have not realized the PET/MRI [ Time Frame: 7 days ]
- number of patients with good quality of the imaging [ Time Frame: 7 days ]The interpretability of the imaging will be evaluated by a Review Committee (two pairs composed each by a radiologist (for MRI imaging) and a nuclear physician (for PET imaging)). The imaging will be classified under good or bad quality
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03977896
|Contact: Pierre-Aurélien BEURIAT, MD||4 27 85 62 20 ext +33||pierre-aurélien.email@example.com|
|Contact: Valérie LAUDYfirstname.lastname@example.org|
|Hospices Civils de Lyon - Groupement Hospitalier Est - Hôpital Femme Mère Enfant - Service de Neurochirurgie Pédiatrique||Not yet recruiting|
|Contact: Pierre-Aurélien BEURIAT pierre-aurélien.email@example.com|
|Principal Investigator:||Pierre-Aurélien BEURIAT, MD||Hospices Civils de Lyon|